thing chang
updat forecast estim may
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research may
estim may
price data may
rate updat may
currenc amount express
valuat growth profit
methodolog valu compani
stori one constant chang firm
found manufactur compon wwii aircraft
final divest industri busi full
transit medic devic thereaft leadership
ceo benson smith compani complet transit
industri conglomer pure-play medic devic manufactur
core busi focus vascular surgeri
firm strategi effect carv nich market
compet thu far remain rel insul
intens competit largest player med-tech
manag target market opportun
compani suppli dispos product
mandatori
procedur creat rel stabl demand associ
cash flow addit product portfolio primarili contain
low dollar valu item along increment innov
allow compani improv margin profil modest
price inflat time combin like-for-lik price
power smith character direct market access core
tenant compani strategi led slowli
acquir foreign distribut partner provid better line
sight end market allow firm captur otherwis
lost distributor margin lead sustain predict gross
smith intend retir end anticip
strategi like remain unchang incom ceo current
liam kelli recent acquisit vascular solut
neotract help improv firm margin profil believ
high price paid limit contribut near
term addit grow goodwil compon firm
invest capit base held histor return wacc
wed like see evid compani trend toward
sustain econom profit gener award moat
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
inc wayn pennsylvania base manufactur hospit
suppli medic devic primarili within vascular access
surgic area firm report eight primari segment vascular north
america sale intervent north america
asia oem geograph exposur
busi primarili account revenu
intern market make remaind
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
thing chang
host investor day may provid deep
dive firm busi segment outlin
manag multi-year outlook compani base
heard expect chang firm
come year plan chang no-moat rate
fair valu estim ceo liam kelli
first major platform lay goal set cours
leadership sens firm
strategi kelli remain larg similar
former ceo benson smith expect kelli focu
drive improv organ growth invest
firm core compet cathet anesthesia
manag surgic equip expand
margin via cost ration increas presenc
direct distribut intern strategi like
augment combin tuck-in acquisit
substanti deal improv compani product
line exist vertic help expand adjac
time dedic assess urolift
devic acquir firm purchas neotract
came away better understand product
competit posit bit confid
outlook present given two urologist
use product firsthand said
consolid revenu growth forecast touch higher
manag outlook period
margin estim slightli lower fundament view
firm stock unchang free cash flow
estim fall within manag expect
million averag free cash gener
annual forecast roughli
billion cumul free cash flow period
like alloc toward continu restructur
firm dividend acquisit opportun time
discuss urolift like give investor
someth increment consid somewhat
disappoint mani product highlight
remain unchang firm last investor day
bone marrow biopsi product acquir
firm acquisit vidacar percutan
laparoscopi system antimicrobi peripher
cathet area consist highlight
manag appreci value-add product
bring clinician patient howev hope
needle-mov given firm current
product portfolio consist tens-of-thousand sku
growth potenti
necessarili new manag discuss
around freeze-dri plasma product acquir
vascular solut acquisit provid bit context
come year
manag anticip fda submiss earli
provid organ growth guidanc
suggest product provid modest
increment top-lin contribut medium term
think current equiti valuat fulli discount healthi
upsid manag outlin growth margin
assumpt would await compel entri
point consid share
valuat growth profit feb
digest result slightli
rais fair valu estim per share
roll model updat assumpt
believ primari differ model
market view attribut valuat premium
associ potenti unannounc acquisit
time time estim adjust
earn ebitda sale respect line
valuat bard receiv acquisit becton
dickinson believ market use proxi
valu valuat method valu
firm exist stand-alone basi without imput
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
expect margin expans come follow
area addit gross margin vascular solut
account basi point forecast acquisit
estim gross margin neotract add
approxim basi point given outsiz growth
profil core margin improv make
remain basi point expect core
improv come approxim basi point
cost reduct attribut alreadi announc
restructur initi expect complet
remain basi point stem
continu progress distributor-to-direct convers
given uncertainti creat integr sizabl
acquisit complet cours
increas risk associ arguabl stretch
balanc sheet rate uncertainti high
bull case incorpor busi fundament valuat
believ would like associ
acceler period enhanc growth
profil vascular solut neotract result
compound-annual-growth-rate forecast period addit
assum manag oper margin target
realiz year sooner base case estim
result valu per share approxim time
time time bull-cas forecast
adjust earn ebitda revenu respect
bear-cas forecast contempl scenario
sizabl impair goodwil would like occur
case forecast slow core revenu growth less
stellar contribut recent acquisit
result revenu compound-annual-growth-rate line busi
done last three year near addit
estim restructur effort fail meaning
expand core gross margin oper expens
level fail meet exist synergi target
premium estim probabl take-out
addit discount cash flow methodolog
incorpor cash outflow announc -- someth
believ rel multipl base approach like
updat outlook project busi continu
solid perform anticip firm grow
revenu near compound-annual-growth-rate forecast period
meaning ahead prior three-year compound-annual-growth-rate near
outlook newli acquir vascular solut
neotract busi drive expect
acceler growth addit add nearli
respect growth core revenu base
addit improv gross margin mix
addit busi inform expect
nearli basi point gross margin gain
baselin one-for-on drop oper
profit forecast consist manag
aspir goal oper margin eclips
come year
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
still expect oper margin expand case
forecast fall short manag target
result valuat per share
yet clear us abl
success dig moat firm develop lead
posit hand market acquisit
dont yet confid meaning
outperform estim wacc decad
believ compani competit posit conting
manag abil sourc valu integr futur
acquisit constitut basi
moat histor profil support
stanc -- prior acquisit yet materi
enhanc firm return given substanti goodwil
alloc recur cost relat integr
restructur effort suggest deal valuat
expens side wed like see
evid valu creation adjust current view
howev think manag strategi target
product low absolut price point effect
hospit continu becom
sensit firm product portfolio somewhat uniqu
item carri sticker price less
believ help insul busi
industrywid price pressur thu far actual
allow compani rais price modestli time
howev believ manag act
price opportun avail compani assum
price benefit go forward mix relat rather
like-for-lik price power view firm vascular
surgic anesthesia franchis area like
develop futur moat firm respiratori
oem busi rather commodit
overal focus acquir product
top three four competitor make gener
two third total market vascular access
cathet laryng mask laparoscop surgeri
gener compet hand firm
mani case lead product arrow
line central cathet lma laryng mask portfolio
competit posit current favor
clear firm develop sourc
advantag give us confid abil defend
better capit competitor
medic suppli industri gener view
switch cost intang asset cost advantag
like sourc underpin competit moat
focus enhanc product portfolio
acquisit isnt support moat
isol view dont see evid
moat sourc present product portfolio
center around low-cost single-us product reli
physician prefer group purchas group gpo
contract repeat sale deepli ingrain
switch cost either procur administr
end user addit firm margin profil
on-going manufactur consolid restructur
effort suggest us uniqu cost advantag current
exist -- although anticip margin improv
come year manag optim compani
addit hesit award moat base
underinvest research develop
compar peer sinc transit pure play
medic busi compani spent
revenu averag research develop effort
versu peer bard
spent nearer high-single-digit percentag
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
revenu basi multipl
abl spend absolut dollar us impli
 compon strategi outsiz
impact rel competitor believ
put firm disadvantag environ
attract acquisit hard come
appear manag appetit acquisit
acceler cours close two deal
billion total valu think
deal includ interest asset dont believ
combin inher enhanc valu
combin compani competit posit expect
addit vascular solut neotract
improv firm growth margin profil howev
concern valuat paid limit
accret near term dont anticip impli
return sharehold deal exceed
estim firm cost capit three four
year doesnt jump us obvious value-add
proposit addit neotract repres one
riski opportun taken given
billion all-in price singl product firm
year commerci launch
view underli moat trend stabl
compani enjoy modest share gain year
undergon acquisit enhanc
firm posit tangenti market believ
product ad uniqu opportun
product portfolio dont view inclus
asset sustain improv weaken
underli competit posit
busi
addit valuat paid look expens
side rather obviou bargain calcul
manag commentari
accret combin near term us
limit return improv suggest underli
moat sourc unlik improv inclus
acquisit alon
believ potenti upsid exist base-cas
assumpt regard acquisit particularli
case neotract given larg unmet need within
benign prostat hyperplasia bph market want
remain cogniz bigger pictur believ teleflex
need continu sourc acquisit backfil
 pipelin increas uncertainti regard
develop platform abil busi
respond effect competit pressur view
addit either recent deal fail meet
expect believ materi risk capit
base given current make-up compani balanc
sheet case intang asset goodwil
make nearli total asset valu versu peer closer
averag pursu similar strategi
monitor progress deal
chang firm-wide care evid
posit neg inflect assess
final concern focus
product market limit barrier entri
product littl way intang
regul framework minim switch
cost outsid inertia part hospit procur
administr favor gpo relationship combin
underinvest intern worri
defens firm current market posit
given size scope primari competitor
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
gross margin profil meaning
improv higher margin vascular solut
neotract begin out-grow core franchis
clinic benefit area unmet need market
opportun substanti could repres home-
run acquisit sale continu grow current
product portfolio competit strategi
resembl bard could make
viabl take-out candid given bard pend tie
balanc sheet reach restrict
level manag pay debt
next year two return
acquisit could hamstr near-term
ohistor acquisit yet materi
compani profil given
substanti goodwil alloc -- verdict still
manag capit alloc prowess
goodwil intang asset much
larger portion balanc sheet compar
peer pursu similar strategi could indic
over-pay histor deal
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
level
view financi health reason
although recent acquisit activ rais leverag
histor
debt-to-adjust ebitda stood near time
account neotract acquisit modestli ahead
time rang compani oper
last year believ compani strong cash
flow profil along continu growth oper
leverag allow compani comfort de-lever
time adjust ebitda tax reform
firm access liquid markedli improv
vast major balanc sheet cash held oversea
estim firm approxim million
tax-affect pension oblig nearli million
balanc sheet leas financ modestli worsen
billion gross debt estim teleflex
time howev believ compani adequ
access liquid form million annual free
cash flow along million current avail
revolv line credit
assign high uncertainti rate due heavili
indebt balanc sheet recent acquisit
increas risk otherwis stabl cash flow
profil near term would highlight potenti
valu destruct post-leadership transit
rel unconcern possibl given kelli
tenur addit expect integr
vascular solut neotract produc
wacc return capit within year high price
paid creat meaning risk capit base expect
growth fail materi addit highlight
risk stem firm limit invest
realiz return intern activ view
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
compani intern develop engin somewhat
lack would highlight materi underinvest
 vs peer spent roughli sale
 averag last five year versu bard
north becton dickinson near
better averag fill gap
acquisit anticip continu
find value-add candid critic firm
success go forward addit believ signific
portion compani product portfolio limit
protect custom switch cost enhanc
risk firm current market posit view
market environ provid acquisit
candid new manag team fail effect
sourc opportun think risk put
structur competit disadvantag time
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
share
fund
share
fund
award manag team standard mark
stewardship due success firm
leadership benson smith tenur ceo sinc
smith serv board member sinc
elev ceo role mark end histori
industri conglomer signal board
support firm strateg evolut pure-play
devic experi c-suit spent
nearli year career bard includ
late believ manag effect
alloc sharehold capit year
acquisit divestitur activ build
medic portfolio also like nich product
strategi compani pursu larg
insul busi price pressur seen broadli
across industri last year
howev smith year-end retir ceo role
preclud us award team except rate
although new ceo liam kelli part
compani execut team sinc held titl
sinc wed like get better sens
strateg vision capit alloc strategi firm
overal view manag compens reason
believ interest manag team
align minor sharehold insid
ownership encourag corpor director
offic own outstand share includ
underli option rsu smith own
annual
compens structur includ roughli equiti
base pay meaning vest period view
posit annual option grant vest ratabl
three-year period annual rsu vest entireti
three-year period perform metric base
compani addit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
primarili annual revenu ep target combin
weight tie oper cash flow
remain individu target think
consist mani compani cover wed
prefer heavier emphasi cash flow return capit
opinion better measur corpor
perform adjust incom statement item
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
first quarter bring chang outlook
report mix quarter view slightli
exceed revenu growth off-set modestli higher
oper expens manag rais top- bottom-
line outlook back more-favorable-than-anticip
currenc chang announc new restructur
profit consid move part
updat model well like leav fair valu estim
no-moat firm unchang
consolid
footprint
report revenu growth rather
encourag nearli driven due favor
currenc fluctuat quarter addit littl
constant currenc revenu growth
percentag point attribut inorgan
contribut firm combin vascular
solut vsi acquir midway first-quart
neotract close earli fourth quarter last
year back neg contribut
sell day varianc quarter quarter impact
product line divestitur organ revenu growth
firm ran line initi guidanc full
year importantli firm lap acquisit vsi
midway first quarter mean
includ organ growth go forward best
estim suggest reclassif lift teleflex
organ growth rate basi point remaind
year
turn oper expens much growth like
attribut sale support neotract busi
surpris lack leverag given product
growth rate quarter total expenditur came
ahead estim non- basi
plan rais expenditur outlook modestli
remaind year
manag announc restructur plan appear
solid invest like see much way
materi profit improv least earli
plan expect requir roughli million
cash outlay next six year result
million pre-tax save complet roughli
return invest program core
tenet integr strategi last hand
year undergon multipl iter
gener addit corpor gross
oper margin level hope obtain detail
relat specif investor day schedul
may
continu struggl valuat stock
estim us appear quit headi
valuat compani grow revenu mid-single-
digit organ clip layer acquir higher-growth
asset give manag credit modest oper
leverag boost earn growth low-double-
digit come five year stock appear price
perfect leverag level roughli time
quarter annual adjust ebitda earn qualiti
arguabl deterior wed wait convinc
margin safeti consid share
report in-lin growth remain
no-moat report fourth-quart full-year
result fell squar within expect
provid guidanc slightli better
initi outlook thank impact favor currenc
movement mani move part
updat roll model includ report segment
reorgan anticip major chang
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
could ultim neg adjust tax rate
high teen histor final note
compani debt structur includ roughli billion
floating-r instrument could present interest
expens headwind rate rise expect throughout
fair valu estim
view thesi center organ
outlook busi disappoint quarter
compar new product introduct price volum
combin year-over-year growth
guidanc seem impli true base busi organ
growth rate near slightli estim
becom increasingli difficult teas
report vascular solut get fold
soft quarter driven distributor
destock revers throughout
concern broader deceler vascular
solut seen two consecut quarter
growth substanti double-digit run rate
report acquisit yet call
trend believ perform busi line
key indic monitor given histori
pay acquisit drive improv perform
asset vital sharehold valu creation
posit note recent close acquisit
neotract continu impress growth trajectori
beat initi sale expect roughli million
full year howev substanti higher oper
expens structur requir support manag
expect growth target busi weigh
profit adjust sell gener
administr expens enterpris grew nearli
manag oper margin outlook fell line
forecast slightli better gross margin
perform expect off-set higher oper
expens base like due integr neotract
addit manag anticip firm modest
net beneficiari tax reform someth thought
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
